Loading clinical trials...
Loading clinical trials...
Expression/DNA Methylation of Cancer Testis Antigens May Predict Response to Pembrolizumab in Non-small Cell Lung Cancer Patients
Conditions
Interventions
PD-L1 positive vs PD-L1 negative NSCLC patients
Locations
1
Austria
Medical University of Vienna
Vienna, Austria
Start Date
February 10, 2020
Primary Completion Date
January 14, 2021
Completion Date
July 14, 2021
Last Updated
June 11, 2020
NCT07485114
NCT06066138
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Medical University of Vienna
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions